<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/D5DF5258-6FC1-4F92-928B-2E970FF914D4"><gtr:id>D5DF5258-6FC1-4F92-928B-2E970FF914D4</gtr:id><gtr:name>The University of Iowa</gtr:name><gtr:address><gtr:line1>203 Van Allen Hall</gtr:line1><gtr:line4>Iowa City</gtr:line4><gtr:line5>IA 52242-1479</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/B143DFC4-584C-454D-919D-D0712EDC026F"><gtr:id>B143DFC4-584C-454D-919D-D0712EDC026F</gtr:id><gtr:name>University of Muenster (Munster)</gtr:name><gtr:address><gtr:line1>University of Muenster</gtr:line1><gtr:line2>Schlossplatz 2</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Institute of Neurology</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D5DF5258-6FC1-4F92-928B-2E970FF914D4"><gtr:id>D5DF5258-6FC1-4F92-928B-2E970FF914D4</gtr:id><gtr:name>The University of Iowa</gtr:name><gtr:address><gtr:line1>203 Van Allen Hall</gtr:line1><gtr:line4>Iowa City</gtr:line4><gtr:line5>IA 52242-1479</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/B143DFC4-584C-454D-919D-D0712EDC026F"><gtr:id>B143DFC4-584C-454D-919D-D0712EDC026F</gtr:id><gtr:name>University of Muenster (Munster)</gtr:name><gtr:address><gtr:line1>University of Muenster</gtr:line1><gtr:line2>Schlossplatz 2</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/72B12262-3A96-46C3-A2CC-DA2E64AB8A00"><gtr:id>72B12262-3A96-46C3-A2CC-DA2E64AB8A00</gtr:id><gtr:firstName>Nikolaus</gtr:firstName><gtr:surname>Weiskopf</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/3D1ADC06-3827-4DAF-8A60-D83A8AAFAC1B"><gtr:id>3D1ADC06-3827-4DAF-8A60-D83A8AAFAC1B</gtr:id><gtr:firstName>Geraint</gtr:firstName><gtr:otherNames>Ellis</gtr:otherNames><gtr:surname>Rees</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/EA6F1C3B-4178-4448-AE25-8B3BFBF2384E"><gtr:id>EA6F1C3B-4178-4448-AE25-8B3BFBF2384E</gtr:id><gtr:firstName>Ralf</gtr:firstName><gtr:surname>Reilmann</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/09E0B5AB-60CC-47FB-B71E-B9368698C5AC"><gtr:id>09E0B5AB-60CC-47FB-B71E-B9368698C5AC</gtr:id><gtr:firstName>Marina</gtr:firstName><gtr:surname>Papoutsi</gtr:surname><gtr:roles><gtr:role><gtr:name>RESEARCHER</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/CF2C874A-1644-469C-A7D1-9F2F660E27ED"><gtr:id>CF2C874A-1644-469C-A7D1-9F2F660E27ED</gtr:id><gtr:firstName>Jon</gtr:firstName><gtr:surname>Telfer</gtr:surname><gtr:roles><gtr:role><gtr:name>RESEARCHER</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/7ADD968D-1D63-4687-B530-A7EC95C89DDF"><gtr:id>7ADD968D-1D63-4687-B530-A7EC95C89DDF</gtr:id><gtr:firstName>Sarah</gtr:firstName><gtr:otherNames>Joanna</gtr:otherNames><gtr:surname>Tabrizi</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/B479AF28-6702-46F0-9E6E-FB582FB91FDA"><gtr:id>B479AF28-6702-46F0-9E6E-FB582FB91FDA</gtr:id><gtr:firstName>Douglas</gtr:firstName><gtr:otherNames>Robert</gtr:otherNames><gtr:surname>Langbehn</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=MR%2FL012936%2F1"><gtr:id>F5D0195E-DA9B-43B6-B081-AA0A10115A25</gtr:id><gtr:title>Improving function in Huntington's disease through neurofeedback: using real-time fMRI to enhance cortical plasticity in early stages of the disease</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/L012936/1</gtr:grantReference><gtr:abstractText>Huntington's disease (HD) is a rare, inherited, neurological condition where progressive brain damage leads to severe difficulties with movement, emotion and thought. The most characteristic sign of HD is uncontrolled movement of the limbs but subtle movement, emotion and thinking difficulties can start many years before this. There is no known cure for HD; a few drug treatments can help with some of the symptoms but have many deleterious side effects.

HD is characterized by slow, progressive atrophy of the brain, which theoretically allows the brain the opportunity to re-organize and compensate for the disease-related structural and functional changes. In this proposal, we will develop state-of-the-art technologies using functional magnetic resonance imaging (fMRI) and biofeedback to enhance such compensation and potentially alleviate symptoms. fMRI is a well-known technique that allows activity in the brain to be recorded non-invasively while people perform a task. Normally the analyses of these data are carried out off-line over a period of several weeks. However, recent developments allow real-time analysis of brain images and enable us to feed back the level of activity in selected brain areas to an individual while they lie in the brain scanner. Such real-time feedback can be used to train people to control their own brain activity through repeated sessions where they learn to enhance the activity that is fed back. This has been successfully used to allow people to control activity in many different regions of the brain and has also been applied to clinical conditions such as Parkinson's disease, depression and pain management with encouraging initial results for symptom management.

In this proposal we will use such advanced neurofeedback fMRI techniques to train individuals with symptomatic HD to control the level of activity in motor cortex, or the coupling of motor cortex with areas deep in the brain that are affected early in HD. Our underlying hypothesis is that if individuals with HD can learn to regulate the activity of brain regions that underpin their disease and contribute to the manifestation of certain symptoms, then the symptoms should improve.

Apart from the urgent need for new therapies, one advantage of studying HD is that genetic testing can establish with 100% accuracy whether an individual carries the mutant gene and will therefore develop HD at some point in their life. This enables us to not only monitor disease progression many years before an individual manifests the disease (pre-symptomatic stage), but also to develop interventions that can be applied at very early stages of the disease, when the brain damage is still limited and function is still well preserved. We know that structural and functional brain changes precede the manifestation of overt clinical signs by many years. This means that there is a mechanism of compensation at work, enabling gene-carriers to maintain a normal level of function despite degeneration. As the disease progresses and brain atrophy increases, this mechanism starts to break down and clinical signs start to become more evident. This is another gradual process and pre-symptomatic HD gene-carriers gradually move to a peri-symptomatic phase (with soft motor signs and mild cognitive impairment) and then eventually express unequivocal signs of the disease.

Our aim is to determine through a proof of concept study that the training protocol can be tolerated and followed by HD patients, and show that the intervention can improve symptoms in early stage HD. If the results are positive we will then proceed to develop this intervention more generally for both early and pre-symptomatic stages of the disease. Because neurofeedback training is a non-invasive intervention with no side effects, it is an ideal candidate for both pre-symptomatic treatment and in combination with other treatments at later stages of the disease.</gtr:abstractText><gtr:technicalSummary>Huntington's disease (HD) is a genetic, neurodegenerative condition that leads to extensive brain atrophy, starting from the striatum and gradually spreading throughout the brain. Clinically it is characterized by progressive motor impairment, e.g. chorea, cognitive decline and neuropsychiatric symptoms. There is currently no known cure for HD and treatments prescribed for symptom management have significant side-effects. This project will deliver &amp;quot;proof of concept&amp;quot; testing of a novel, non-invasive intervention: neurofeedback training using real-time functional MRI (rt-fMRI), which will induce neuroplasticity and could help patients better manage the disease symptoms. Patients will be scanned using fMRI and will be trained to regulate the activity of specific brain regions through receiving in-scanner real-time feedback about the activity of these regions. We hypothesise that training patients to regulate the activation of brain regions whose activity has been disrupted by the disease (e.g. premotor cortex and striatum), will lead to improvements in behaviour and slowed disease progression. Such rt-fMRI has already been used for the treatment of other clinical conditions (e.g. Parkinson's disease, chronic pain, depression) with positive results on behaviour and symptom management without any side-effects. The proposed study will be the first &amp;quot;proof of concept&amp;quot; for HD and will provide preliminary evidence on the feasibility and efficacy of the intervention in early stage HD. If the results are positive, then these data will support further development with a large scale, randomized controlled trial in both early stage and premanifest HD. HD is an excellent model of neurodegenerative diseases as there is a precise genetic test, which allows prospective study of disease progression particularly in the premanifest phase. Our results may therefore have broad applicability and be extrapolated to other more common neurodegenerative diseases such as Alzheimer's disease.</gtr:technicalSummary><gtr:potentialImpactText>The proposed project is the collaborative effort between different research groups working on MRI physics, HD and cognitive neuroscience. As such the results from the project are relevant to not only the HD research and patient community, but also to research in neuroplasticity, brain functional reserve and neuroimaging methods for the study of neuroplasticity. At present neurofeedback training is being tested as treatment for and has already partly demonstrated efficacy in Parkinson's disease (Subramanian et al., 2011), depression (Linden et al., 2012) and chronic pain management (deCharms et al., 2005). Therefore our systematic approach to training and technical improvements will be highly beneficial for these applications and for the further development of neurofeedback training using rt-fMRI in the clinical setting more generally. 

If our results are positive, we expect to actively involve supportive MRI manufacturers (see letter of support by Siemens), who will be able to deploy this technology in the clinical setting through integration into MRI scanner software. Dr Weiskopf has a long-standing collaboration with Siemens and is PI on a joint academia-industry project with Siemens on implementation of novel scanning methods for clinical use.

Developments in the technology of rt-fMRI, such as increase in signal to noise and contrast to noise ratio and prospective head motion correction, will also be relevant for other applications of rt-fMRI, other than neurofeedback training. One such application is the communication with locked-in patients to establish whether a patient is in a vegetative or locked-in state. Improvements in rt-fMRI technology will provide a better tool for communication with these patients.

In HD, we have predictive genetic testing that can establish with absolute certainty whether a person will develop the disease later in life, therefore HD is a good model for research in the development of a preventative treatment. Neurofeedback training is a safe preventative treatment that could be also used for other neurodegenerative conditions, where there are identifiable risk factors, but no clear diagnosis prior to symptom onset, such as Alzheimer's disease. Therefore the outcomes of the research will be of interest in the development of low-risk preventative treatments for other neurodegenerative diseases as well.</gtr:potentialImpactText><gtr:fund><gtr:end>2018-01-16</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2014-03-17</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1056075</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Iowa</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Professor Doug Langbehn</gtr:description><gtr:id>738DC9D4-764C-43AF-A9A8-A4109E623C9D</gtr:id><gtr:impact>We were successful in being awarded the MRC DPFS grant Ref: MR/L012936/1.</gtr:impact><gtr:partnerContribution>Provided Statistical support/advise</gtr:partnerContribution><gtr:piContribution>Provided experimental dataset</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Muenster</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Professor Ralf Reilmann</gtr:description><gtr:id>B5CF0ACE-3268-44E6-9799-B6DA46D3B6CA</gtr:id><gtr:impact>We were awarded the MRC DPFS grant Ref: MR/L012936/1</gtr:impact><gtr:partnerContribution>Provided support with motor assessments and equipment</gtr:partnerContribution><gtr:piContribution>Provided experimental dataset</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Presented poster at European Huntington's Disease Network 2016 Conference , The Hague</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3E36D6DD-523A-4FB7-B622-87B2A9935C72</gtr:id><gtr:impact>Presented poster titled: 'Compensation in preclinical huntington's disease: evidence from the track-on HD study. Gregory S., Kl&amp;ouml;ppel S., Scheller E., Minkova L., Razi A., Durr A., Roos R., Leavitt BR., Papoutsi M., Landwehrmeyer B., Reilmann R., Borowsky B., Johnson H., Mills JA., Owen G., Stout J., Scahill RI., Long JD., Rees G., Tabrizi SJ' . Generated questions from staff members</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CAG Triplet Repeat Disorders, Tuscany, Italy</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C5BDB0D8-2085-4415-9BFE-0D66B117734F</gtr:id><gtr:impact>Presented talk on HD research to scientific peers and healthcare professionals</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Royal College of Psychiatrists International Congress 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>CF7E3331-67C5-4063-AAA6-107D81EC0264</gtr:id><gtr:impact>Presented education lecture on 'What have we learnt about compensatory neural networks from large HD cohort studies' to healthcare practitioners</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presented poster at European Huntington's Disease Network 2016 Conference, The Hague</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F0A4C328-8706-4AD2-826E-C89103331B57</gtr:id><gtr:impact>Presented poster titled 'Operationalising compensation over time in Neurodegenerative Disease. Gregory S., Long JD., Kl&amp;ouml;ppel S., Razi A., Scheller E., Minkova L., Papoutsi M., Mills J., Durr A., Leavitt BR, Roos RAC, Stout J., Scahill RI, Langbehn DR, Tabrizi SJ, Rees'

Generated questions from audience</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presented talk a Lancet Neurology Conference 2017, London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4F576C8D-82A1-4EF3-8CE8-B05ACDEEF200</gtr:id><gtr:impact>Presented talk entitled 'Gene silencing approaches for Huntington's disease'. Generated questions and audience discussions.

Prof Tabrizi also organised this meeting</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presented talk at 28th Cambridge Neuroscience Seminar, Cambridge University</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>B6EEBDD5-4708-4FE2-A6D5-CF7D92894461</gtr:id><gtr:impact>Presented talk entitled 'Meeting the therapeutic challenge in Huntington's disease'</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>25th International Symposium on ALS/MND, Brussels</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0F991D57-9FAB-41E5-BEF8-F132CB6144CB</gtr:id><gtr:impact>Presented educational talk on HD to MNDA members</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presented talk at Hereditary Disease Foundation, The Milton Wexler Celebration of Life Symposium 2017, Massachusetts</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F70D5EDF-AC06-49D6-B944-59E32DCA37BA</gtr:id><gtr:impact>Presented talk entitled 'Early Clinical Development of IONIS-HTTR'. Talk generated questions and audience discussion</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>RSM Medical Genetics Talk</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>3F4D46F1-7EFC-4E92-9343-6923C80F70B3</gtr:id><gtr:impact>Presented educational talk as part of course for healthcare professionals.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presented talk at Kings College London Neuroscience Society 'Wiring Together: Neuroplasticity in the brain' conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>5701D17B-E28E-47DE-BAF0-E9DC548A7616</gtr:id><gtr:impact>Presented talk titled 'HD Brain-Train: neuroplasticity as a target to improve function in in Huntington's Disease'. Generated questions from attendees</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presented talk at Huntington Study Group Conference and Satellite Symposium, Nashville</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>55EA9E84-59E1-4B58-86CB-E44DEB401AA3</gtr:id><gtr:impact>Presented talk entitled &amp;quot;Neuroimaging endpoints for HD studies and Track-HD data&amp;quot;. Talk generated questions and audience discussion</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Huntington's Disease Association's HD Certified Course Programme</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>2E93E18F-D50B-4C69-9728-761BD28974E1</gtr:id><gtr:impact>Presented talk on Neurology in Huntington's Disease to health care professionals working in Huntington's Course as part of HDA Certified Course</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Present talk at European Huntington's Disease Network Conference 2016, The Hague</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>07EF59EA-F054-42A6-B6BC-43B56F1D41D7</gtr:id><gtr:impact>Presented talk entitled 'Gene targeting therapies for Huntington's disease'. Generated talk questions and audience discussion</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Article/interview in the Telegraph regarding compensation paper</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>265F977B-6273-4B63-A7AB-7F94DAFC0375</gtr:id><gtr:impact>Interview and article in the Telegraph re HD compensation paper. Served to expose research to wider audience. 

Kl&amp;ouml;ppel S1, Gregory S2, Scheller E3, Minkova L3, Razi A4, Durr A5, Roos RA6, Leavitt BR7, Papoutsi M8, Landwehrmeyer GB9, Reilmann R10, Borowsky B11, Johnson H12, Mills JA13, Owen G8, Stout J14, Scahill RI8, Long JD15, Rees G16, Tabrizi SJ8; Track-On investigators. Compensation in Preclinical Huntington's Disease: Evidence From the Track-On HD Study. EBioMedicine. 2015 Aug 4;2(10):1420-9. doi: 10.1016/j.ebiom.2015.08.002. eCollection 2015.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://hdresearch.ucl.ac.uk/wp-content/uploads/Telegraph-Article.jpg</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presented talk at Imperial College Neuroscience Society's Conference 2017</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>38FCD6E6-0566-4A34-9AF5-DDB9363A353A</gtr:id><gtr:impact>Presented talk titled 'Meeting the therapeutic challenge in Huntington's disease'. Generated questions and audience discussion</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Chair of clinical trial session at CHDI 11 Annual Conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8EE6B4C3-5FE1-482E-BA72-C4C56112E76D</gtr:id><gtr:impact>Chaired clinical trial blitz session which sparked debates and questions from audience which included students, charitable donrs and industry representatives</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Study participants or study members</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Ionis Trial press release</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>22E062AC-D8B1-4E5E-AB91-7674AB9F185D</gtr:id><gtr:impact>Press release regarding the commencement of the IONIS-HTT-Rx trial. Resulted in media coverage from the BBC, The Times and other national and international publishers and broadcasters.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:url>http://www.bbc.co.uk/news/health-34552041</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>1st Congress of the EAN, Berlin</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5F9D86C4-FA02-4F1B-85B6-72951D6A9A89</gtr:id><gtr:impact>Talk on HD research presented to students, scientists and healthcare practitioners.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presented talk at Oxford University Departmental Seminar</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>DD16F52A-4381-4B34-96F3-AA0F662870F4</gtr:id><gtr:impact>Presented talk entitled 'Meeting the Therapeutic Challenge in Huntington's disease'. Generated questions from audience and discussion</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Poster presentation at OHBM 2014 Annual Meeting (Hamburg, Germany).</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1A0C9D6C-C2BA-470D-B3EC-A0F45D717FBB</gtr:id><gtr:impact>Presented poster. Generated questions from attendees:

Papoutsi M., Weiskopf N., Langbehn D., Reilmann R., Rees G., Tabrizi S.J. (2014): 
Neural re-organisation in Huntington's disease using real-time fMRI neurofeedback training. 
OHBM 2014 Annual Meeting (Hamburg, Germany).</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presented poster at EHDN Plenary meeting</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8986005A-1B12-40AE-BF3A-F5A90C3FE176</gtr:id><gtr:impact>Presented poster at EHDN plenary meeting. Generated questions for attendees

Papoutsi M., Weiskopf N., Langbehn D., Reilmann R., Rees G., Tabrizi S.J. (2014): Brain
Training in HD: Enhancing neural plasticity using real-time fMRI neurofeedback training. 8Th
EHDN Plenary meeting (Barcelona, Spain). Journal of Neurology, Neurosurgery &amp;amp;
Psychiatry, 85(S1), A65-A66</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presented talk at 11th Warsaw International Medical Congress for Young Scientists, Medical University of Warsaw</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C552154F-2082-4D6B-A261-0944106BEAF8</gtr:id><gtr:impact>Presented talk entitled ''Meeting the therapeutic challenge in Huntington's disease'. Generated questions and discussion with audience</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>EHDN 2014 Plenary Meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F867E65A-9EE2-449A-82BD-70AA77BF03CE</gtr:id><gtr:impact>Invitations and talks of this nature serve to enhance engagement with my research

Various</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Huntington Study Group Presentation, Tampa</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>221276B6-D4E2-423F-960C-2E6EE1DC7411</gtr:id><gtr:impact>Presented education talk on ongoing clinical trials to HD researchers and clinicians, industry representatives, and advocacy organizations. Talk generated many questions and interest. Aided study/trial planning.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presented talk at Association of British Neurologists Special Interest Group Meeting 2017, London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B832FB5C-A74F-4CD4-AA23-75FC51F75661</gtr:id><gtr:impact>Presented talk entitled &amp;quot;Silencing abnormal proteins&amp;quot;. Generated discussion and questions from the audience</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Annual Penney Lecture, Massachusetts General Hospital, Harvard</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E986B5E1-2EC5-4AAF-A6F7-420374986917</gtr:id><gtr:impact>Presented prestigious Jack Penney Lecture sparking questions from a range of students and scientists</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>18th International Congress of Parkinson's Disease and Movement Disorders</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0E0352D0-F519-4928-922C-EC9F9C88E4B7</gtr:id><gtr:impact>Invitations and talks of this nature serve to enhance engagement with my research

Various</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Clinical Neurosciences Alumni Day, Royal Free Hospital1</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>0759C51D-DEAF-419F-B738-6C6FDB5B4726</gtr:id><gtr:impact>Presented educational course to healthcare professionals.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presneted talk at CASMI / UCLH BRC / UCL Personalised Medicine Domain Symposium 2017, London, UK</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>0EF9E1C4-A044-4156-B433-B54BF61F904F</gtr:id><gtr:impact>Presented talk entitled 'Cellular and gene therapies'. Generated questions and discussion with audience</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presented poster also selected for oral presentation  XXII Congress of the European Society for Stereotactic and Functional Neurosurgery (Madrid, Spain)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>AF4287F6-AC81-4749-B70E-CF00304CD1B5</gtr:id><gtr:impact>Presented poster titled 'Short-term intensive neurofeedback training using realtime fMri in pre-operative parkinson's disease patients. Jinendra Ekanayake, Marina Papoutsi, Joerg Magerkurth, Oliver Josephs, Catherine Milbao, Marjan Jahanshahi, Patricia Limousin, Tom Foltynie, Geraint Rees, Ludvic Zrinzo'. Poster generated discussions and invite for oral presentation</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presented talk at &quot;20th International Congress of Parkinson's Disease and Movement Disorders, Berlin&quot;</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0241EA67-CCDC-4586-8E73-1159581146C1</gtr:id><gtr:impact>Presented talk entitled 'Complex phenotypes and genotypes - seeing the wood for the trees, presentation titled Huntington's disease and HD-like disorders'. Generated audience discussion and questions</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presented talk at European Huntington's Disease Network 2016 Conference, The Hague</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6E186E73-A308-4A37-A770-465BC6BBA97E</gtr:id><gtr:impact>Presented talk entitled 'HD Brain-Train: neuroplasticity as a target to improve function in in Huntington's Disease'. Generated questions from audience</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Centre for Neuromuscular Diseases Seminar Series 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>797BC494-8FE0-48EA-9A8C-3E7CE041275A</gtr:id><gtr:impact>Presented talk on therapeutic strategies in HD to students and professional practitioners alike. The talk generated lot's of interest and questions.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Brains Talk Seminar at Roche</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4DE77277-E767-4623-BECB-BB04518C1955</gtr:id><gtr:impact>Presented seminar on Hutington's Disease to Roche Pharmaceuticals to aid company strategic planning</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presented poster at BNA 2015 conference</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F778005C-220A-4261-BC39-0BBF735BAF5A</gtr:id><gtr:impact>Presented poster at BNA 2015 Conference. Generated questions from attendees:

04/2015 Papoutsi M., Weiskopf N., Rees G., Tabrizi S.,: Neurofeedback training in Huntington's disease: 
enhancing neural plasticity using real-time fMRI neurofeedback training .</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>HD2014: The Milton Wexler Celebration of Life Symposium.</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>660F127C-9664-4640-A90B-4170160408C3</gtr:id><gtr:impact>Engagements and talks of this nature serve to enhance engagement with my research

Various</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Key Advances in Neurodegenerative Disorders Meeting, Royal Society of Medicine</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>33FEE05C-E62D-44EA-9574-59C65AB60806</gtr:id><gtr:impact>Presented education talk on HD to healthcare professionals</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presented talk at Division of Brain Sciences, Imperial College London, Charing Cross Hospital</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2D181DA3-4799-4EF2-8F29-9AC86F0DF4DC</gtr:id><gtr:impact>Presented talk entitled &amp;quot;Meeting the Therapeutic Challenge in Huntington's disease&amp;quot;. Talk generated questions and audience participation</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation at WTCN workshop on realtime fMRI Neurofeedback at UCL</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>8E1E7F41-737A-4BC7-9554-CD3C1A9CE458</gtr:id><gtr:impact>Presnted talk at workshop.Generated questions from attendees:


Papoutsi M., Weiskopf N., Rees G., Tabrizi S.,: Brain Training in Huntington's
disease: Enhancing neural plasticity using real-time fMRI neurofeedback
training.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CHDI 10th Annual HD Therapeutics Conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2F469CD9-0278-4611-B12A-6C940BDB768E</gtr:id><gtr:impact>Presented talk on HD studies to researchers, healthcare practitioners and students.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>HD Website</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>70E4B768-055B-49F8-8DEA-30958D14BAE4</gtr:id><gtr:impact>Articles of this nature serve to enhance engagement with my research

Positive feedback from patients and healthcare professionals</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation at BNA 2015 Festival of Neuroscience</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>97C65C10-341F-4163-BEAB-D8966F411B77</gtr:id><gtr:impact>Presented talk at BNA workshop. Generated questions from attendees:

Papoutsi M., Weiskopf N., Rees G., Tabrizi S.,: Brain Training in Huntington's
disease: Enhancing neural plasticity using real-time fMRI neurofeedback
training. Workshop called &amp;quot;Closing the Loop: Brain Computer Interfaces and
Neurofeedback&amp;quot;.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Research open day held at the UCLH</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>5FA3967A-26E3-46F3-8777-56A247B4146A</gtr:id><gtr:impact>The Tabrizi stall attracted a good number of visitors.

The day was briefly mentioned in the Guardian on-line</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presented talk at UCL SLMS 2016 Clinical Academic Trainees Symposium, London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>BEFAAFCB-9C25-435D-867B-3A5C1BBC3C23</gtr:id><gtr:impact>Presented talk entitled 'Gene silencing approaches for Huntington's disease'. Talk generated questions and audience discussions.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presented poster at European Huntington's Disease Network  2016 Conference, The Hague</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>61A4B6FD-05DA-4C7F-A154-82210A5A7CA0</gtr:id><gtr:impact>Presented poster titled 'HD Brain-Train: neuroplasticity as a target to improve function in in Huntington's Disease Papoutsi M., Weiskopf N., Langbehn D., Reilmann R., Rees G., Tabrizi S.J.'

Generated questions from Audience</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1342343</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Targeting the innate immune system in Huntington's disease</gtr:description><gtr:end>2018-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/L02053X-1</gtr:fundingRef><gtr:id>77388834-50B6-4EDE-8542-C121FC4325A7</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>151903</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Wellcome Trust Research Training Fellowship</gtr:department><gtr:description>Research Training Fellowship. Basal ganglia network degeneration and cortical network compensation in Huntington's disease.</gtr:description><gtr:end>2017-07-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:fundingRef>103437/Z/13/Z</gtr:fundingRef><gtr:id>9D5664E5-08C7-4A46-9F2A-A5F71E535593</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>All Party Parliamentary Group (APPG) in Huntington's Disease</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>75FDECF1-3620-436F-AF28-0FAA5B9B8B87</gtr:id><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/992077F6-564B-49E1-AA0F-8A0B3316E89D"><gtr:id>992077F6-564B-49E1-AA0F-8A0B3316E89D</gtr:id><gtr:title>Medication Use in Early-HD Participants in Track-HD: an Investigation of its Effects on Clinical Performance.</gtr:title><gtr:parentPublicationTitle>PLoS currents</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e12e27d3e0fb1f4fbf524b30573d11aa"><gtr:id>e12e27d3e0fb1f4fbf524b30573d11aa</gtr:id><gtr:otherNames>Keogh R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/977D7A14-FA59-4CE2-8E84-17A04F99EA44"><gtr:id>977D7A14-FA59-4CE2-8E84-17A04F99EA44</gtr:id><gtr:title>Detection of Motor Changes in Huntington's Disease Using Dynamic Causal Modeling.</gtr:title><gtr:parentPublicationTitle>Frontiers in human neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f5bfe42ebf8aad656e577b22007c52e7"><gtr:id>f5bfe42ebf8aad656e577b22007c52e7</gtr:id><gtr:otherNames>Minkova L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1662-5161</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/43CCC936-61C3-465D-80A5-C8E4E045445E"><gtr:id>43CCC936-61C3-465D-80A5-C8E4E045445E</gtr:id><gtr:title>Large-scale brain network abnormalities in Huntington's disease revealed by structural covariance.</gtr:title><gtr:parentPublicationTitle>Human brain mapping</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f5bfe42ebf8aad656e577b22007c52e7"><gtr:id>f5bfe42ebf8aad656e577b22007c52e7</gtr:id><gtr:otherNames>Minkova L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1065-9471</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D4639B2B-158B-47AD-94FF-9BC25D82E9AE"><gtr:id>D4639B2B-158B-47AD-94FF-9BC25D82E9AE</gtr:id><gtr:title>Basal ganglia-cortical structural connectivity in Huntington's disease.</gtr:title><gtr:parentPublicationTitle>Human brain mapping</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/44b9220f49dff6ea9205d964cd07638a"><gtr:id>44b9220f49dff6ea9205d964cd07638a</gtr:id><gtr:otherNames>Novak MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1065-9471</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2CB19C53-EB00-49EE-B143-B23DEDE2998B"><gtr:id>2CB19C53-EB00-49EE-B143-B23DEDE2998B</gtr:id><gtr:title>Natural variation in sensory-motor white matter organization influences manifestations of Huntington's disease.</gtr:title><gtr:parentPublicationTitle>Human brain mapping</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9697b4cede3cd59594423f38cd663145"><gtr:id>9697b4cede3cd59594423f38cd663145</gtr:id><gtr:otherNames>Orth M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1065-9471</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F2072233-3BF8-456E-8C5B-AA889D6561BE"><gtr:id>F2072233-3BF8-456E-8C5B-AA889D6561BE</gtr:id><gtr:title>Huntington disease.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Disease primers</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/46a6d340b1c9dd22889424ee21a45141"><gtr:id>46a6d340b1c9dd22889424ee21a45141</gtr:id><gtr:otherNames>Bates GP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2056-676X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/40942DB8-2AE8-4C36-838B-D1DB602E4715"><gtr:id>40942DB8-2AE8-4C36-838B-D1DB602E4715</gtr:id><gtr:title>Visuospatial Processing Deficits Linked to Posterior Brain Regions in Premanifest and Early Stage Huntington's Disease.</gtr:title><gtr:parentPublicationTitle>Journal of the International Neuropsychological Society : JINS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d09744033873b2243ec07cccf31fe9bc"><gtr:id>d09744033873b2243ec07cccf31fe9bc</gtr:id><gtr:otherNames>Labuschagne I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1355-6177</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AFFFC6DD-C08A-495D-AC75-838B7BB02E51"><gtr:id>AFFFC6DD-C08A-495D-AC75-838B7BB02E51</gtr:id><gtr:title>Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c2ad55e1a2ad1526b8ced1a4945eda9d"><gtr:id>c2ad55e1a2ad1526b8ced1a4945eda9d</gtr:id><gtr:otherNames>Wild EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F5D88BB6-E977-4183-B88C-87DCB4DC7DE5"><gtr:id>F5D88BB6-E977-4183-B88C-87DCB4DC7DE5</gtr:id><gtr:title>Brain Mapping</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d271c4aa5ab11326832c2cffb80b7910"><gtr:id>d271c4aa5ab11326832c2cffb80b7910</gtr:id><gtr:otherNames>Tabrizi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/58051C71-1899-40C8-AF97-17FD363DCF74"><gtr:id>58051C71-1899-40C8-AF97-17FD363DCF74</gtr:id><gtr:title>Short-interval observational data to inform clinical trial design in Huntington's disease.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5cb8a78e67b2350728fe64236392c6db"><gtr:id>5cb8a78e67b2350728fe64236392c6db</gtr:id><gtr:otherNames>Hobbs NZ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CAEBBE1F-C5F0-4959-AA18-DA72EE518759"><gtr:id>CAEBBE1F-C5F0-4959-AA18-DA72EE518759</gtr:id><gtr:title>Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington's disease gene carriers.</gtr:title><gtr:parentPublicationTitle>Neurobiology of disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/003ef0c2090080af16a9718d5168846f"><gtr:id>003ef0c2090080af16a9718d5168846f</gtr:id><gtr:otherNames>Politis M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0969-9961</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/695EB5FA-AC94-4445-BE91-382A59629EAA"><gtr:id>695EB5FA-AC94-4445-BE91-382A59629EAA</gtr:id><gtr:title>Neuropsychiatry and White Matter Microstructure in Huntington's Disease.</gtr:title><gtr:parentPublicationTitle>Journal of Huntington's disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/089465fdee6ce32f4c3e04ff20830e80"><gtr:id>089465fdee6ce32f4c3e04ff20830e80</gtr:id><gtr:otherNames>Gregory S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1879-6397</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E3EB367F-66F6-4DC2-9AC9-EBDB13469F4E"><gtr:id>E3EB367F-66F6-4DC2-9AC9-EBDB13469F4E</gtr:id><gtr:title>Longitudinal Diffusion Tensor Imaging Shows Progressive Changes in White Matter in Huntington's Disease.</gtr:title><gtr:parentPublicationTitle>Journal of Huntington's disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/089465fdee6ce32f4c3e04ff20830e80"><gtr:id>089465fdee6ce32f4c3e04ff20830e80</gtr:id><gtr:otherNames>Gregory S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1879-6397</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DD916152-C89B-4DD3-ADBF-1E0F68F3F2EE"><gtr:id>DD916152-C89B-4DD3-ADBF-1E0F68F3F2EE</gtr:id><gtr:title>Cerebellar abnormalities in Huntington's disease: a role in motor and psychiatric impairment?</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b9d58bb04e03e62baa42def4034f85fc"><gtr:id>b9d58bb04e03e62baa42def4034f85fc</gtr:id><gtr:otherNames>Rees EM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C4EE6C12-38E7-46F2-8BF3-2ED2174130D3"><gtr:id>C4EE6C12-38E7-46F2-8BF3-2ED2174130D3</gtr:id><gtr:title>The Prevalence of Huntington's Disease.</gtr:title><gtr:parentPublicationTitle>Neuroepidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/745563f85829dbaa1965e22c06d1b78b"><gtr:id>745563f85829dbaa1965e22c06d1b78b</gtr:id><gtr:otherNames>Rawlins MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0251-5350</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/563C3CB2-6ACC-4755-BD7F-E3E82208A3E0"><gtr:id>563C3CB2-6ACC-4755-BD7F-E3E82208A3E0</gtr:id><gtr:title>A SNP in the HTT promoter alters NF-?B binding and is a bidirectional genetic modifier of Huntington disease.</gtr:title><gtr:parentPublicationTitle>Nature neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1e1cfb4bd351abd15ff6bc9b0d8ca8c1"><gtr:id>1e1cfb4bd351abd15ff6bc9b0d8ca8c1</gtr:id><gtr:otherNames>Becanovic K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1097-6256</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3A1B324B-54EA-4F36-BA92-2B2082AD584F"><gtr:id>3A1B324B-54EA-4F36-BA92-2B2082AD584F</gtr:id><gtr:title>Identification of Genetic Factors that Modify Clinical Onset of Huntington's Disease.</gtr:title><gtr:parentPublicationTitle>Cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/24844b94ce9ccf8895c174d7e28d81c1"><gtr:id>24844b94ce9ccf8895c174d7e28d81c1</gtr:id><gtr:otherNames>Genetic Modifiers of Huntington's Disease (GeM-HD) Consortium</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0092-8674</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/089C90B3-2DD3-46DE-A082-BAE09AC4219A"><gtr:id>089C90B3-2DD3-46DE-A082-BAE09AC4219A</gtr:id><gtr:title>Altered PDE10A expression detectable early before symptomatic onset in Huntington's disease.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d698f86e284d2fbf178db44297e68a50"><gtr:id>d698f86e284d2fbf178db44297e68a50</gtr:id><gtr:otherNames>Niccolini F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/39FBD7B9-0D6A-41E4-A4C6-EF8EB83799A9"><gtr:id>39FBD7B9-0D6A-41E4-A4C6-EF8EB83799A9</gtr:id><gtr:title>DNA repair pathways underlie a common genetic mechanism modulating onset in polyglutamine diseases.</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9960cd808582e52821f0e586e2ba9176"><gtr:id>9960cd808582e52821f0e586e2ba9176</gtr:id><gtr:otherNames>Bettencourt C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D72A30D9-4EC3-4A73-92BA-17B03BB2124E"><gtr:id>D72A30D9-4EC3-4A73-92BA-17B03BB2124E</gtr:id><gtr:title>White matter predicts functional connectivity in premanifest Huntington's disease.</gtr:title><gtr:parentPublicationTitle>Annals of clinical and translational neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/12bd802931db2c434b281e1bc64f66fc"><gtr:id>12bd802931db2c434b281e1bc64f66fc</gtr:id><gtr:otherNames>McColgan P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2328-9503</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EC3BC2B8-F31C-4C3A-968B-E274EC3646F6"><gtr:id>EC3BC2B8-F31C-4C3A-968B-E274EC3646F6</gtr:id><gtr:title>The neuroanatomy of subthreshold depressive symptoms in Huntington's disease: a combined diffusion tensor imaging (DTI) and voxel-based morphometry (VBM) study.</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6ca477d7fb0f336d34ba94effe3e69d2"><gtr:id>6ca477d7fb0f336d34ba94effe3e69d2</gtr:id><gtr:otherNames>Sprengelmeyer R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/57C0740E-1D88-491B-952E-D456B79F5153"><gtr:id>57C0740E-1D88-491B-952E-D456B79F5153</gtr:id><gtr:title>Incidence of adult Huntington's disease in the UK: a UK-based primary care study and a systematic review.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/72f33eb26c0be7cf921722580f404c3c"><gtr:id>72f33eb26c0be7cf921722580f404c3c</gtr:id><gtr:otherNames>Wexler NS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B84F02AE-F67F-41C3-A80F-2838CAD6F3D4"><gtr:id>B84F02AE-F67F-41C3-A80F-2838CAD6F3D4</gtr:id><gtr:title>Compensation in Preclinical Huntington's Disease: Evidence From the Track-On HD Study.</gtr:title><gtr:parentPublicationTitle>EBioMedicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0db57caf0730d369d7172f0f5c17a375"><gtr:id>0db57caf0730d369d7172f0f5c17a375</gtr:id><gtr:otherNames>Kl?ppel S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2352-3964</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B9A3A1E3-6E0A-4005-A657-3C21CCAF2AF3"><gtr:id>B9A3A1E3-6E0A-4005-A657-3C21CCAF2AF3</gtr:id><gtr:title>Selective vulnerability of Rich Club brain regions is an organizational principle of structural connectivity loss in Huntington's disease.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/12bd802931db2c434b281e1bc64f66fc"><gtr:id>12bd802931db2c434b281e1bc64f66fc</gtr:id><gtr:otherNames>McColgan P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C9DC85DB-4A88-41AA-AA75-7C81AF6CD06E"><gtr:id>C9DC85DB-4A88-41AA-AA75-7C81AF6CD06E</gtr:id><gtr:title>Analysis of White Adipose Tissue Gene Expression Reveals CREB1 Pathway Altered in Huntington's Disease.</gtr:title><gtr:parentPublicationTitle>Journal of Huntington's disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/19e574f7e92402bb2fe15089a7580366"><gtr:id>19e574f7e92402bb2fe15089a7580366</gtr:id><gtr:otherNames>McCourt AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1879-6397</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C8F0B9FA-7EF2-401E-97DF-34ADE9AF8648"><gtr:id>C8F0B9FA-7EF2-401E-97DF-34ADE9AF8648</gtr:id><gtr:title>A longitudinal study of magnetic resonance spectroscopy Huntington's disease biomarkers.</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b3c3eb2bef22cfe2ba16541b470af2d5"><gtr:id>b3c3eb2bef22cfe2ba16541b470af2d5</gtr:id><gtr:otherNames>Sturrock A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/81A66603-4F20-47CD-A965-C73EB3A0503F"><gtr:id>81A66603-4F20-47CD-A965-C73EB3A0503F</gtr:id><gtr:title>Task-specific training in Huntington disease: a randomized controlled feasibility trial.</gtr:title><gtr:parentPublicationTitle>Physical therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/836ab228d0a2d9cab611cd19460e2edc"><gtr:id>836ab228d0a2d9cab611cd19460e2edc</gtr:id><gtr:otherNames>Quinn L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0031-9023</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/62424E7A-2EFA-43AD-8B5F-F2C71E256B49"><gtr:id>62424E7A-2EFA-43AD-8B5F-F2C71E256B49</gtr:id><gtr:title>Inconsistent emotion recognition deficits across stimulus modalities in Huntington?s disease.</gtr:title><gtr:parentPublicationTitle>Neuropsychologia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b9d58bb04e03e62baa42def4034f85fc"><gtr:id>b9d58bb04e03e62baa42def4034f85fc</gtr:id><gtr:otherNames>Rees EM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-3932</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A0D80A16-3FE1-4B23-B4A5-BB03589E3323"><gtr:id>A0D80A16-3FE1-4B23-B4A5-BB03589E3323</gtr:id><gtr:title>The impact of occipital lobe cortical thickness on cognitive task performance: An investigation in Huntington's Disease.</gtr:title><gtr:parentPublicationTitle>Neuropsychologia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/857c42fb5eb62fac1fd3ba85ccb3e671"><gtr:id>857c42fb5eb62fac1fd3ba85ccb3e671</gtr:id><gtr:otherNames>Johnson EB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0028-3932</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/L012936/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>AAFE74BF-2594-40A4-9487-23A469C7A3C4</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.6  Psychological and behavioural</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>